Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Dahkki Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Dahkki Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Dahkki Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... Dahkki Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. Dahkki Diana M. Hendrickx (1507435)

Aerosol Capture for Coupling to Microfluidics: A Miniaturized Low-Cost Device for Size-Resolved Particle Collection Dahkki Yao Xiao (227567)

Gender differences among various self-harm variables. Dahkki Willie Njoroge (20623714)

Fáttát:

Trends in the valuation of injury involving the face: an analysis on trial in Rio Grande do Sul, Brazil Dahkki Gabriela Cauduro da ROSA (4647883)

“…To measure the damage, the assessment of the bodily harm is required. Objective To analyze jurisprudential characteristics involving the valuation of the damage related to facial trauma, highlighting trends Methods It was analyzed secondary data, which are public domain, of the precedents of the Court of Justice of Rio Grande do Sul State from 2008 to 2016. …”

PRLR1 is involved in mediating dsRNA-response in <i>adar1(RNAi)</i> and <i>adar2(RNAi)</i> animals. Dahkki Dan Bar Yaacov (11965433)

Votes in favor of lifting COVID-19 measures (Experiment 2). Dahkki Besarta Veseli (12289504)

Fáttát: